HK1064108A1 - Agent for the prevention and treatment of sexually transmitted diseases-i - Google Patents

Agent for the prevention and treatment of sexually transmitted diseases-i

Info

Publication number
HK1064108A1
HK1064108A1 HK04106895.9A HK04106895A HK1064108A1 HK 1064108 A1 HK1064108 A1 HK 1064108A1 HK 04106895 A HK04106895 A HK 04106895A HK 1064108 A1 HK1064108 A1 HK 1064108A1
Authority
HK
Hong Kong
Prior art keywords
treatment
agent
sexually transmitted
prevention
transmitted diseases
Prior art date
Application number
HK04106895.9A
Other languages
English (en)
Inventor
Barry Ross Matthews
George Holan
Peter Karellas
Scott Andrew Henderson
David Francis O'keefe
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of HK1064108A1 publication Critical patent/HK1064108A1/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Peptides Or Proteins (AREA)
HK04106895.9A 2001-03-30 2004-09-10 Agent for the prevention and treatment of sexually transmitted diseases-i HK1064108A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR4128A AUPR412801A0 (en) 2001-03-30 2001-03-30 Agent for the prevention and treatment of sexually transmitted disease s - I
PCT/AU2002/000407 WO2002079299A1 (en) 2001-03-30 2002-03-28 Agent for the prevention and treatment of sexually transmitted diseases-i

Publications (1)

Publication Number Publication Date
HK1064108A1 true HK1064108A1 (en) 2005-01-21

Family

ID=3828128

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106895.9A HK1064108A1 (en) 2001-03-30 2004-09-10 Agent for the prevention and treatment of sexually transmitted diseases-i

Country Status (15)

Country Link
US (2) US7589056B2 (xx)
EP (1) EP1399499B1 (xx)
JP (1) JP4216076B2 (xx)
KR (1) KR100882343B1 (xx)
CN (1) CN1305931C (xx)
AT (1) ATE426001T1 (xx)
AU (2) AUPR412801A0 (xx)
BR (1) BRPI0208411B8 (xx)
CA (1) CA2441357C (xx)
DE (1) DE60231616D1 (xx)
ES (1) ES2324600T3 (xx)
HK (1) HK1064108A1 (xx)
MX (1) MXPA03008909A (xx)
NZ (1) NZ528230A (xx)
WO (1) WO2002079299A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
CN1778967B (zh) * 2004-11-25 2010-11-10 中国科学院化学研究所 抑制hiv-1反式激活蛋白与反式激活应答序列rna结合用的聚酰胺-胺型树状化合物
AU2006303860C1 (en) * 2005-10-18 2016-01-21 Starpharma Pty Limited Microbicidal dendrimer composition delivery system
ES2937113T3 (es) 2006-01-20 2023-03-24 Starpharma Pty Ltd Macromolécula modificada
ES2558875T3 (es) * 2006-03-22 2016-02-09 Starpharma Pty Limited Composición anticonceptiva
ES2834916T3 (es) * 2006-08-11 2021-06-21 Starpharma Pty Ltd Agente terapéutico dirigido de dendrímero de polilisina
EP2076557A4 (en) * 2006-08-11 2012-08-29 Starpharma Pty Ltd POLYLYSINE DENDRIMER CONTRAST AGENT
JP2008202025A (ja) * 2007-01-22 2008-09-04 Honda Motor Co Ltd プロトン伝導性高分子
JP2008270177A (ja) 2007-03-23 2008-11-06 Honda Motor Co Ltd プロトン伝導体
IT1395137B1 (it) 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
US8251452B2 (en) * 2009-11-13 2012-08-28 Hill Jason D Gaming chairs
CA2836168C (en) * 2011-05-16 2019-09-24 Starpharma Pty Ltd Method of treatment or prophylaxis of bacterial vaginosis
CN105007910B (zh) 2012-09-13 2019-03-19 星法马有限公司 眼部感染的治疗或预防药物的制造用途
BR112018072741A2 (pt) * 2016-05-05 2019-02-19 Starpharma Pty Ltd método para a profilaxia de infecção pelo vírus da zika
CN110305188B (zh) * 2018-03-23 2020-03-13 广州朗圣药业有限公司 一种预防hiv感染的新化合物及其制备方法
EP3823961A4 (en) * 2018-07-19 2022-06-08 Starpharma Pty Limited THERAPEUTIC DENDRIMER
CN114053394B (zh) * 2020-07-30 2024-06-21 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
CN114053392B (zh) * 2020-07-30 2024-06-21 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗hpv感染的药物中的应用
CN114053393B (zh) * 2020-07-30 2024-06-28 广州朗圣药业有限公司 一种药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4558120A (en) * 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US7572459B2 (en) * 1998-09-14 2009-08-11 Starpharma Pty Ltd. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
AUPP584398A0 (en) 1998-09-14 1998-10-08 Starpharma Limited Inhibition of toxic materials or substances
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
WO2001036328A1 (en) * 1999-11-18 2001-05-25 Exxon Chemical Patents Inc. Method for the synthesis of molecular sieves
US6893506B2 (en) * 2002-03-11 2005-05-17 Micron Technology, Inc. Atomic layer deposition apparatus and method

Also Published As

Publication number Publication date
MXPA03008909A (es) 2005-03-07
US20050008611A1 (en) 2005-01-13
NZ528230A (en) 2006-02-24
DE60231616D1 (de) 2009-04-30
US7589056B2 (en) 2009-09-15
JP4216076B2 (ja) 2009-01-28
CA2441357C (en) 2011-05-31
EP1399499B1 (en) 2009-03-18
CA2441357A1 (en) 2002-10-10
KR20040027506A (ko) 2004-04-01
AU2002245932B2 (en) 2007-04-05
ATE426001T1 (de) 2009-04-15
BRPI0208411B1 (pt) 2016-06-28
CN1503816A (zh) 2004-06-09
AUPR412801A0 (en) 2001-05-03
US20090269298A1 (en) 2009-10-29
BRPI0208411B8 (pt) 2021-05-25
EP1399499A4 (en) 2004-09-29
EP1399499A1 (en) 2004-03-24
WO2002079299A1 (en) 2002-10-10
US8158575B2 (en) 2012-04-17
CN1305931C (zh) 2007-03-21
JP2004532211A (ja) 2004-10-21
KR100882343B1 (ko) 2009-02-12
BR0208411A (pt) 2004-03-30
ES2324600T3 (es) 2009-08-11

Similar Documents

Publication Publication Date Title
HK1064108A1 (en) Agent for the prevention and treatment of sexually transmitted diseases-i
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
CA98023S (en) Bottle
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PT1411908E (pt) Tratamento de infeccoes da unha com no
WO2002041837A3 (en) Treatment of mucositis
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
WO2002076499A3 (en) Combination treatment of pancreatic cancer
WO2005039630A3 (en) Immunogenic compositions
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
TR200402670T4 (tr) Obezitenin tedavisi ve/veya profilaksına uygun bileşiklerin bulunması için yöntem
EP1441761A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF INFECTIONS WITH THE FLAVIRUS IN ANIMALS
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
WO2002040001A3 (en) Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane
WO2003007914A3 (en) Biocompatible polymer containing composition for treatment of prostate cancers
BR0111785A (pt) Composições e métodos para tratamento de candidìase
IL148856A0 (en) Novel fluoroalkylsubstituted cyclotrisiloxanes, their use for preparation of new polymers and novel polymers
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis
EP1174469A3 (de) Lineare Polydialkylorganosiloxane mit Polyoxyalkylen- und aminofunktionellen Gruppen, die zusätzlich endständige Alkoxygruppen aufweisen

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220327